FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938493431> ?p ?o ?g. }

• W2938493431 abstract "Abstract Introduction Triple-negative breast cancers are a poor prognostic group of breast cancers that don’t respond to conventional hormonal and her2neu targeted therapy. A subset of triple-negative breast cancer is known to overexpress epidermal growth factor receptor (EGFR); however prognostic significance of this biomarker has not been widely studied in our population. Therefore, we aimed to evaluate the frequency of EGFR overexpression in triple-negative breast cancer in our setup and its association with prognostic and predictive factors. Methods We performed EGFR immunohistochemistry on 150 cases of triple-negative breast cancers. Intensity and percentage of EGFR expression were combined to formulate an EGFR score, that was compared with prognostic features of breast cancer and recurrence status of patients. Results Positive EGFR expression was noted in 18.7% ( 28 cases); out of which 16% (24 cases) showed low EGFR expression, whereas high EGFR expression was seen in 2.7% ( 4 cases). No significant association of EGFR expression was noted when compared with various clinicopathological parameters and recurrence status of the patients. Conclusion We found EGFR protein expression in 18.7% of cases while high expression was seen in only 2.7 % cases of triple-negative breast cancer which may harbor underlying genetic alterations like altered EGFR gene copy number, chromosome 7 copy number or average EGFR gene: chromosome 7 ratio; therefore we suggest that molecular tests like FISH to evaluate these EGFR molecular alterations should be performed in EGFR over expressing triple negative breast cancers in our setup to identify patients that can benefit from anti-EGFR targeted therapy. Moreover, regional difference in EGFR expression (high expression in chinese population compared to our population) are may be due to different underlying genetic alterations in triple-negative breast cancers, further necessitating a need of devising personalized therapeutic protocols for locoregional population." @default.
• W2938493431 created "2019-04-25" @default.
• W2938493431 creator A5029079456 @default.
• W2938493431 creator A5041556478 @default.
• W2938493431 creator A5041815210 @default.
• W2938493431 creator A5056504199 @default.
• W2938493431 creator A5057348486 @default.
• W2938493431 creator A5058034163 @default.
• W2938493431 creator A5088339992 @default.
• W2938493431 creator A5088479660 @default.
• W2938493431 date "2019-02-08" @default.
• W2938493431 modified "2023-10-17" @default.
• W2938493431 title "Epidermal growth factor receptor (EGFR) overexpression in triple-negative breast cancer: association with clinicopathologic features and prognostic parameters" @default.
• W2938493431 cites W1968036127 @default.
• W2938493431 cites W1974685860 @default.
• W2938493431 cites W1983953368 @default.
• W2938493431 cites W1988055795 @default.
• W2938493431 cites W2001388083 @default.
• W2938493431 cites W2006122819 @default.
• W2938493431 cites W2009453033 @default.
• W2938493431 cites W2042166975 @default.
• W2938493431 cites W2054062143 @default.
• W2938493431 cites W2054212440 @default.
• W2938493431 cites W2069336962 @default.
• W2938493431 cites W2072279625 @default.
• W2938493431 cites W2083527129 @default.
• W2938493431 cites W2093287293 @default.
• W2938493431 cites W2093812166 @default.
• W2938493431 cites W2101979288 @default.
• W2938493431 cites W2130252153 @default.
• W2938493431 cites W2136776783 @default.
• W2938493431 cites W2140831826 @default.
• W2938493431 cites W2140996395 @default.
• W2938493431 cites W2143716848 @default.
• W2938493431 cites W2158863975 @default.
• W2938493431 cites W2327837002 @default.
• W2938493431 cites W2727009687 @default.
• W2938493431 cites W2797325286 @default.
• W2938493431 cites W2806041148 @default.
• W2938493431 cites W2810237915 @default.
• W2938493431 cites W4234081105 @default.
• W2938493431 doi "https://doi.org/10.1186/s42047-018-0029-0" @default.
• W2938493431 hasPublicationYear "2019" @default.
• W2938493431 type Work @default.
• W2938493431 sameAs 2938493431 @default.
• W2938493431 citedByCount "20" @default.
• W2938493431 countsByYear W29384934312020 @default.
• W2938493431 countsByYear W29384934312021 @default.
• W2938493431 countsByYear W29384934312022 @default.
• W2938493431 countsByYear W29384934312023 @default.
• W2938493431 crossrefType "journal-article" @default.
• W2938493431 hasAuthorship W2938493431A5029079456 @default.
• W2938493431 hasAuthorship W2938493431A5041556478 @default.
• W2938493431 hasAuthorship W2938493431A5041815210 @default.
• W2938493431 hasAuthorship W2938493431A5056504199 @default.
• W2938493431 hasAuthorship W2938493431A5057348486 @default.
• W2938493431 hasAuthorship W2938493431A5058034163 @default.
• W2938493431 hasAuthorship W2938493431A5088339992 @default.
• W2938493431 hasAuthorship W2938493431A5088479660 @default.
• W2938493431 hasBestOaLocation W29384934311 @default.
• W2938493431 hasConcept C104317684 @default.
• W2938493431 hasConcept C120821319 @default.
• W2938493431 hasConcept C121608353 @default.
• W2938493431 hasConcept C126322002 @default.
• W2938493431 hasConcept C141231307 @default.
• W2938493431 hasConcept C142724271 @default.
• W2938493431 hasConcept C143998085 @default.
• W2938493431 hasConcept C204232928 @default.
• W2938493431 hasConcept C2779438470 @default.
• W2938493431 hasConcept C2780110267 @default.
• W2938493431 hasConcept C2781197716 @default.
• W2938493431 hasConcept C502942594 @default.
• W2938493431 hasConcept C530470458 @default.
• W2938493431 hasConcept C55493867 @default.
• W2938493431 hasConcept C71924100 @default.
• W2938493431 hasConcept C7602840 @default.
• W2938493431 hasConcept C86803240 @default.
• W2938493431 hasConceptScore W2938493431C104317684 @default.
• W2938493431 hasConceptScore W2938493431C120821319 @default.
• W2938493431 hasConceptScore W2938493431C121608353 @default.
• W2938493431 hasConceptScore W2938493431C126322002 @default.
• W2938493431 hasConceptScore W2938493431C141231307 @default.
• W2938493431 hasConceptScore W2938493431C142724271 @default.
• W2938493431 hasConceptScore W2938493431C143998085 @default.
• W2938493431 hasConceptScore W2938493431C204232928 @default.
• W2938493431 hasConceptScore W2938493431C2779438470 @default.
• W2938493431 hasConceptScore W2938493431C2780110267 @default.
• W2938493431 hasConceptScore W2938493431C2781197716 @default.
• W2938493431 hasConceptScore W2938493431C502942594 @default.
• W2938493431 hasConceptScore W2938493431C530470458 @default.
• W2938493431 hasConceptScore W2938493431C55493867 @default.
• W2938493431 hasConceptScore W2938493431C71924100 @default.
• W2938493431 hasConceptScore W2938493431C7602840 @default.
• W2938493431 hasConceptScore W2938493431C86803240 @default.
• W2938493431 hasIssue "1" @default.
• W2938493431 hasLocation W29384934311 @default.
• W2938493431 hasOpenAccess W2938493431 @default.
• W2938493431 hasPrimaryLocation W29384934311 @default.
• W2938493431 hasRelatedWork W1883409887 @default.
• W2938493431 hasRelatedWork W1979058569 @default.

• next